2018
DOI: 10.1056/nejmx180005
|View full text |Cite
|
Sign up to set email alerts
|

Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Abstract: 1 found that the risk of death was not significantly higher with tranexamic acid than with placebo among patients undergoing cardiac surgery. This drug has a class IA indication for bleeding prophylaxis, decreasing the use of blood products and the risk of reintervention. Doses that are less than 50 mg per kilogram of body weight are effective in preventing bleeding as well as in decreasing the inflammatory response that is associated with cardiopulmonary bypass. 2Patients with the 5G/G genotype had a greater … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 1 publication
0
0
0
Order By: Relevance